Glenmark Pharmaceuticals (GLENMARK) Share Price falls 2.01% as stock trades at Rs 2,466.90

Published:   31 August 2026 at 11:49:45 AM IST

Glenmark Pharmaceuticals Share Price declined today as the stock closed at Rs 2,466.90, down 2.01% from the previous close, while the company’s market capitalisation stood at Rs 71,047.24 crore. The session matters because the data confirms a same-day price fall without assigning a company-specific catalyst. For readers tracking Glenmark Pharmaceuticals on Univest, this is a clear price action event that can be read alongside the stock’s valuation, sector context and published financial ratios. Glenmark Pharmaceuticals Share Price Today is therefore best understood through verified numbers rather than assumptions. The move also places Glenmark Pharmaceuticals Stock News in focus for market watchers looking at whether today’s decline aligns with the broader pharmaceutical backdrop or stands out on its own.

Glenmark Pharmaceuticals (GLENMARK) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 2,466.9
Previous Close	Rs 2,517.4
Today's Move	-Rs 50.50 (-2.01%)
Open	Rs 2,535
High	Rs 2,535
Low	Rs 2,454.05
Turnover	Rs 3.4 crore
Market Capitalisation	Rs 71,047.24 crore
Market Cap Category	Large Cap

Glenmark Pharmaceuticals Share Price Today moved from a previous close of Rs 2,517.40 to Rs 2,466.90, a decline of Rs 50.50 or 2.01%. The stock opened at Rs 2,535.00, touched an intraday high of Rs 2,535.00 and a low of Rs 2,454.05. That sequence shows that the day began above the previous close, but the final price finished below it, leaving the session in negative territory.

Turnover was Rs 3.4 crore, which is a factual traded-value figure for the session and should be read as part of the day’s record rather than as an explanation for the fall. Glenmark Pharmaceuticals Share Price therefore reflects a measured decline in the day’s session, with the low of Rs 2,454.05 marking the weakest point in today’s price path. The stock is classified as a Large Cap company in the supplied data, and that market-cap category gives important size context for Glenmark Pharmaceuticals Stock News. In That makes the next step a careful look at valuation and sector positioning.

Glenmark Pharmaceuticals (GLENMARK) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 71,047.24 crore
P/E Ratio	39.52x
P/B Ratio	6.48x
ROE	14.1%
ROCE	20.35%
EPS	Rs 63.7
Book Value Per Share	Rs 388.43
Dividend Yield	0.1%

Glenmark Pharmaceuticals Share Price should also be read against the company’s core financial ratios. The stock’s market capitalisation is Rs 71,047.24 crore, with an enterprise-value style context best understood through the supplied valuation metrics rather than inference. The P/E ratio is 39.52 and the P/B ratio is 6.48, both of which place Glenmark Pharmaceuticals among the more richly valued names in its industry set when compared with the supplied benchmark range. EPS is Rs 63.7, which shows the earnings attributable to each share, while book value is Rs 388.43, indicating the accounting net worth behind each share.

ROE stands at 14.1% and ROCE at 20.35%, both useful as return measures when placed beside peers and sector medians. Dividend yield is 0.1%, a very small historical/current payout measure relative to the share price. Glenmark Pharmaceuticals Share Price therefore combines a higher valuation profile with return ratios that can be compared against the pharmaceutical universe. For Glenmark Pharmaceuticals Stock Analysis, the main point is not a prediction but a factual one: today’s price fall happened in a stock with established profitability metrics and a premium valuation versus several peers. That sets up the ownership and sector lens used by Univest.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	39.52x
Benchmark Median P/E	31.21x
Benchmark Average P/E	48.1x
Benchmark P/E Range	3.7x to 672.45x
Company P/B Ratio	6.48x
Benchmark Median P/B	2.88x
Benchmark Average P/B	4.19x
Company ROE	14.1%
Benchmark Median ROE	11.78%
Benchmark Average ROE	10.68%
Company ROCE	20.35%
Benchmark Median ROCE	13.6%
Benchmark Average ROCE	13.27%
Company Market Capitalisation	Rs 71,047.24 crore
Benchmark Median Market Cap	Rs 670.73 crore
Benchmark Average Market Cap	Rs 14,040.53 crore

In the Healthcare sector and the Pharmaceuticals & Drugs industry, Glenmark Pharmaceuticals Share Price can be compared with a benchmark scope of 203 companies in the same industry. The company’s P/E of 39.52 is above the benchmark median of 31.21 and below the benchmark average of 48.1. Its P/B of 6.48 is above the benchmark median of 2.88 and above the benchmark average of 4.19. ROE at 14.1% is above the benchmark median of 11.78% and above the benchmark average of 10.68%, while ROCE at 20.35% is above the benchmark median of 13.6% and above the benchmark average of 13.27%.

The company’s market capitalisation of Rs 71,047.24 crore is also well above the benchmark median market capitalisation of Rs 670.73 crore and below the benchmark average of Rs 14,040.53 crore when measured across the 203-company scope. This is useful context for Glenmark Pharmaceuticals Share Price Today because it shows how the stock sits within a broad pharmaceutical set that includes many companies with much smaller market values and mixed valuation profiles. In sector terms, Glenmark Pharmaceuticals Stock News today is not about a sector shock; it is about one large listed pharmaceutical company moving lower while still sitting within a valuation framework that is above the industry median on key multiples. Univest readers can use that contrast to understand the session in a wider market setting.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries	SUNPHARMA	4,60,696.31	38.09	5.33	14.85	19.11
Divi's Laboratories	DIVISLAB	2,46,062.83	84.12	13.93	16.19	21.51
Torrent Pharmaceuticals	TORNTPHARM	1,91,515.22	87.81	21.34	26.76	19.27
Zydus Lifesciences	ZYDUSLIFE	1,18,403.7	26.24	4.39	19.69	21.39
Cipla	CIPLA	1,14,554.33	33.99	3.26	11.83	16

Among the supplied peers, Glenmark Pharmaceuticals Share Price sits below Sun Pharmaceutical Industries on market capitalisation but above Zydus Lifesciences, Cipla, Lupin, Aurobindo Pharma and Mankind Pharma on that measure. Its P/E of 39.52 is above Zydus Lifesciences at 26.24, Cipla at 33.99, Lupin at 17.99 and Aurobindo Pharma at 25.57, while it is below Divi's Laboratories at 84.12 and Torrent Pharmaceuticals at 87.81.

On ROE, Glenmark Pharmaceuticals Share Price compares at 14.1%, ahead of Cipla at 11.83, Aurobindo Pharma at 9.93 and Dr. Reddy's Laboratories at 11.69, but below Lupin at 27.11 and Torrent Pharmaceuticals at 26.76. On ROCE, the stock’s 20.35% is above Sun Pharma at 19.11, Cipla at 16 and Dr. Reddy's at 13.75, while below Lupin at 28.86 and Divi's Laboratories at 21.51. For Glenmark Pharmaceuticals Stock Analysis, the peer set shows a company with mid-to-high valuation metrics and solid returns relative to several listed peers.

Why Investors Are Watching Glenmark Pharmaceuticals

• Glenmark Pharmaceuticals Share Price fell 2.01% today to Rs 2,466.90, and the previous close was Rs 2,517.40.
• The day’s range was Rs 2,454.05 to Rs 2,535.00, with the stock opening at Rs 2,535.00.
• Market capitalisation stood at Rs 71,047.24 crore, and Glenmark is classified as a Large Cap company in the supplied data.
• P/E was 39.52, P/B was 6.48, ROE was 14.1% and ROCE was 20.35%.
• In the same industry, Glenmark Pharmaceuticals Share Price is above the benchmark median on P/E, P/B, ROE and ROCE.

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The company is part of a large listed pharmaceutical universe and is compared here against other quoted companies in the same industry set through Univest. Glenmark Pharmaceuticals Share Price Today can therefore be read alongside its market capitalisation of Rs 71,047.24 crore, valuation ratios and return metrics. Glenmark Pharmaceuticals Stock News in this article is strictly based on verified session data and financial ratios supplied in the dataset. For readers following Glenmark Pharmaceuticals Share News, the key is to track the company through its share price, valuation, and industry context rather than through assumptions.

Track Glenmark Pharmaceuticals Share Price on Univest

Use Glenmark Pharmaceuticals (GLENMARK) live share-price page,Univest top decliners screener,Univest market blogs to review live stock data, top decliners and related market analysis.

Univest lets users track Glenmark Pharmaceuticals Share Price, share price live, financial ratios, shareholding pattern, 52-week levels and market insights in one place. You can monitor Glenmark Pharmaceuticals Stock News, Glenmark Pharmaceuticals Latest News and Glenmark Pharmaceuticals Share Price Update through verified market data on Univest.

Frequently Asked Questions

Why is Glenmark Pharmaceuticals Share Price falling today?

Ans.  Glenmark Pharmaceuticals Share Price fell 2.01% to Rs 2,466.90 today, but the supplied data does not establish a company-specific catalyst. The session records the decline, open, high, low, turnover and market capitalisation.

What is Glenmark Pharmaceuticals Share Price today?

Ans.  Glenmark Pharmaceuticals Share Price today is Rs 2,466.90. It was down Rs 50.50 from the previous close of Rs 2,517.40, and the company’s market capitalisation stood at Rs 71,047.24 crore.

What does Glenmark Pharmaceuticals Share Price show on valuation?

Ans.  Glenmark Pharmaceuticals Share Price sits alongside a P/E of 39.52 and a P/B of 6.48. In the same industry benchmark, both multiples are above the median, giving important valuation context.

How does Glenmark Pharmaceuticals compare with peers?

Ans.  Glenmark Pharmaceuticals compares with Sun Pharma, Divi's Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences, Cipla, Lupin, Dr. Reddy's, Aurobindo Pharma and Mankind Pharma on valuation and return ratios. Its P/E and return metrics sit in the middle of the group.

What should investors track next in Glenmark Pharmaceuticals Stock News?

Ans.  Investors can track the next session’s price action, the company’s financial ratios and the same-industry comparison on Univest. Glenmark Pharmaceuticals Share Price will also remain relevant relative to its market capitalisation and profitability metrics.